daraxonrasib

Daraxonrasib (formerly RMC-6236) is Revolution Medicines' oral pan-RAS(ON) inhibitor, and the first targeted therapy to extend overall survival broadly in RAS-mutant pancreatic cancer. In RASolute 302, second-line metastatic PDAC patients on daraxonrasib lived a median 13.2 months versus 6.7 months on chemotherapy (HR 0.40) [1][2]. That result, presented at ASCO 2026, is the reason RVMD carries roughly a $19B market cap. The NDA for 2L metastatic PDAC has been accepted by the FDA under the Commissioner's National Priority Voucher pilot program, and four Phase 3 trials are enrolling across 1L and 2L PDAC, 2L NSCLC, and adjuvant PDAC [3][4][5][6].

Novel small molecule, never approved anywhere. Phase 3 across all major RAS-mutant tumor settings. The FDA granted Breakthrough Therapy Designation for 2L metastatic PDAC with KRAS G12 mutations [12] and Orphan Drug Designation for pancreatic cancer [13]. Fast Track designation has not been publicly disclosed and is likely subsumed by Breakthrough. In October 2025, daraxonrasib was awarded a voucher under the FDA Commissioner's National Priority Voucher (CNPV) Pilot Program - a program launched by the FDA in June 2025 to compress review timelines (target 1-2 months) for a small number of drugs addressing national health priorities [14]. The NDA for 2L metastatic PDAC has been accepted by the FDA under this pathway [15]. EMA has also placed daraxonrasib on its phased-review track [16]. The NEJM publication of RASolute 302 (O'Reilly et al., 2026) formalized the OS and PFS benefit against investigator's-choice chemotherapy [2]. Revolution Medicines has disclosed capital raises and pipeline updates across multiple 8-K filings in 2025-2026 to fund the four concurrent Phase 3s [7]. RxNorm has already assigned CUI 2729828 to the ingredient, unusual for a pre-approval compound but consistent with high anticipated clinical uptake [8].

RAS is a molecular switch that tells cells when to grow. It cycles between an 'off' state (bound to GDP) and an 'on' state (bound to GTP). Mutant RAS gets stuck in the 'on' position and drives constant proliferation. Roughly 90% of pancreatic cancers and 30% of lung adenocarcinomas carry an activating KRAS mutation. Approved KRAS G12C drugs (Amgen's sotorasib, BMS's adagrasib) covalently trap RAS in the 'off' state, but only work on the G12C mutation, which is about 40% of KRAS-mutant NSCLC and under 2% of PDAC. Daraxonrasib does something different: it is a molecular glue that binds cyclophilin A, and the drug-cyclophilin binary complex then clamps onto the 'on' (GTP-bound) state of RAS, blocking effector binding to RAF and also restoring GTP hydrolysis [9][17]. In PDAC, the dominant KRAS alleles are G12D (~40%), G12V (~30%), and G12R (~18%), all within daraxonrasib's pan-G12 target range; the mechanism also covers G12A, G12S, G13, and Q61 variants and the NRAS/HRAS isoforms. G12C is covered by daraxonrasib's mechanism as well, but the RASolve 301 NSCLC trial deliberately excludes G12C ('G12X-non-C') to avoid population overlap with approved G12C-selective agents. Because the binding surface is shared across KRAS, NRAS, and HRAS isoforms and across most G12 variants, one drug hits the mutations that account for roughly 90% of PDAC KRAS drivers. The genetic validation of RAS as an oncology target is as strong as it gets. The RASolute 302 OS curve turns that biology into a survival benefit.

The node NCT is NCT07491445 (RASolute 303), a first-line metastatic PDAC Phase 3 targeting ~900 patients, currently recruiting across the US, Australia, and Japan; estimated primary completion is June 2028 [3]. It has two experimental arms, daraxonrasib monotherapy and daraxonrasib plus gemcitabine/nab-paclitaxel, against a chemotherapy control. Primary endpoints are PFS and OS. The broader Phase 3 program includes RASolute 302 (2L PDAC, complete and positive), RASolve 301 in RAS G12X-non-C NSCLC (NCT06881784, n=590, PFS by BICR vs docetaxel, estimated primary completion December 2027) [4], and RASolute 304 in adjuvant resected PDAC (NCT07252232, n=500, DFS primary, estimated primary completion May 2029) [5]. Design concerns are limited. Endpoints are hard (OS or PFS by blinded central review), populations are biomarker-selected (RAS G12 mutants), and the comparator arms reflect actual standard of care in each setting. The main execution question is enrollment pace for RASolute 303: chemo-only randomization is a harder sell now that positive 2L data exist, and first-line PDAC patients typically accept chemotherapy quickly.

Our model estimates a 23% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and larger-than-typical enrollment for this phase; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

The clearest efficacy risk comes from published resistance data. Aronchik et al. (Nat Med 2026) showed acquired resistance to daraxonrasib emerges in PDAC via multiple convergent routes including secondary RAS mutations and pathway reactivation, and a separate Cell 2026 paper demonstrated disruption of the drug-cyclophilin-RAS molecular glue complex as a resistance mechanism [10][11]. That predicts durable responses will need combinations, and single-agent PFS in 1L may not match the 2L benefit if the combination arm (with gem/nab-pac) becomes the standard-of-care path. Safety risk is on-target: pan-RAS inhibition hits wild-type RAS in normal tissues, driving rash, GI toxicity, and QT effects seen in the Phase 1 program. Rates severe enough to force dose reduction in a first-line population would erode benefit. Execution risk sits in RASolute 303 enrollment (chemo-only randomization is harder post-302) and in RASolve 301 where the RAS G12X-non-C NSCLC population is smaller and more fragmented than PDAC. Commercial risk is muted for PDAC given the OS magnitude but real in NSCLC, where G12C-selective drugs already own the largest KRAS subset. Revolution Medicines is also advancing its own G12C-selective asset elironrasib (RMC-6291) in combination with daraxonrasib in KRAS G12C solid tumors (NCT06128551) [6] - the combination rationale is deeper pathway suppression through simultaneous G12C-selective covalent blockade plus pan-RAS(ON) inhibition, and preclinical data support the doublet in CRC models. This positions RVMD to compete with sotorasib/adagrasib on their own turf rather than ceding G12C entirely.

Watch this closely. RASolute 302 is one of the two or three most important oncology readouts of the decade, and the near-term catalysts are concrete: FDA action on the 2L PDAC NDA (accepted under the CNPV pilot with a target 1-2 month review), the initial approval decision, and interim looks from RASolute 303 (1L PDAC, primary completion June 2028) and RASolve 301 (NSCLC, primary completion December 2027). Addressable market context: US annual metastatic PDAC incidence is roughly 55-60K; ~90% carry a KRAS mutation, and the 2L eligible pool is on the order of 10-15K US patients per year, with a comparable ex-US pool. KRAS G12C oncology precedents (sotorasib, adagrasib) list at roughly $18-25K/month; a pan-RAS drug with an OS benefit in 1L+2L PDAC plus optionality in NSCLC and adjuvant PDAC is what drives sell-side peak worldwide sales estimates for daraxonrasib into the $5-7.6B range [18]. The specific data point that turns this from a great story into a $30B+ company is a positive interim from RASolute 303 showing the 2L OS benefit ports to first-line, ideally with the combination arm outperforming monotherapy against gem/nab-pac. Check back on any Revolution Medicines 8-K disclosure or ASCO/ESMO 2026-2027 abstract submission. Revolution Medicines went from a ~$4B market cap in 2023 to ~$19B on the RASolute 302 print, and the company remains single-asset concentrated: the entire equity story rests on daraxonrasib's franchise expansion. That is the opportunity and the risk in the same sentence. Not investment advice.